Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?

The toll-like receptor (TLR) system constitutes a pylogenetically ancient, evolutionary conserved, archetypal pattern recognition system, which underpins pathogen recognition by and activation of the immune system. Toll-like receptor agonists have long been used as immunoadjuvants in anti cancer imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Killeen, S D, Wang, J H, Andrews, E J, Redmond, H P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360630/
https://www.ncbi.nlm.nih.gov/pubmed/16892041
http://dx.doi.org/10.1038/sj.bjc.6603275
_version_ 1782153096724480000
author Killeen, S D
Wang, J H
Andrews, E J
Redmond, H P
author_facet Killeen, S D
Wang, J H
Andrews, E J
Redmond, H P
author_sort Killeen, S D
collection PubMed
description The toll-like receptor (TLR) system constitutes a pylogenetically ancient, evolutionary conserved, archetypal pattern recognition system, which underpins pathogen recognition by and activation of the immune system. Toll-like receptor agonists have long been used as immunoadjuvants in anti cancer immunotherapy. However, TLRs are increasingly implicated in human disease pathogenesis and an expanding body of both clinical and experimental evidence suggests that the neoplastic process may subvert TLR signalling pathways to advance cancer progression. Recent discoveries in the TLR system open a multitude of potential therapeutic avenues. Extrapolation of such TLR system manipulations to a clinical oncological setting demands care to prevent potentially deleterious activation of TLR-mediated survival pathways. Thus, the TLR system is a double-edge sword, which needs to be carefully wielded in the setting of neoplastic disease.
format Text
id pubmed-2360630
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23606302009-09-10 Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Killeen, S D Wang, J H Andrews, E J Redmond, H P Br J Cancer Minireview The toll-like receptor (TLR) system constitutes a pylogenetically ancient, evolutionary conserved, archetypal pattern recognition system, which underpins pathogen recognition by and activation of the immune system. Toll-like receptor agonists have long been used as immunoadjuvants in anti cancer immunotherapy. However, TLRs are increasingly implicated in human disease pathogenesis and an expanding body of both clinical and experimental evidence suggests that the neoplastic process may subvert TLR signalling pathways to advance cancer progression. Recent discoveries in the TLR system open a multitude of potential therapeutic avenues. Extrapolation of such TLR system manipulations to a clinical oncological setting demands care to prevent potentially deleterious activation of TLR-mediated survival pathways. Thus, the TLR system is a double-edge sword, which needs to be carefully wielded in the setting of neoplastic disease. Nature Publishing Group 2006-08-07 2006-08-01 /pmc/articles/PMC2360630/ /pubmed/16892041 http://dx.doi.org/10.1038/sj.bjc.6603275 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Killeen, S D
Wang, J H
Andrews, E J
Redmond, H P
Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
title Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
title_full Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
title_fullStr Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
title_full_unstemmed Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
title_short Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?
title_sort exploitation of the toll-like receptor system in cancer: a doubled-edged sword?
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360630/
https://www.ncbi.nlm.nih.gov/pubmed/16892041
http://dx.doi.org/10.1038/sj.bjc.6603275
work_keys_str_mv AT killeensd exploitationofthetolllikereceptorsystemincanceradoublededgedsword
AT wangjh exploitationofthetolllikereceptorsystemincanceradoublededgedsword
AT andrewsej exploitationofthetolllikereceptorsystemincanceradoublededgedsword
AT redmondhp exploitationofthetolllikereceptorsystemincanceradoublededgedsword

Ejemplares similares